TGF-β: A critical modulator of immune cell function

Clinical Immunology and Immunopathology

Volumn 84, Issue 3, 1997, Pages 244-250

  Letterio, John J ^a   Roberts, Anita B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

AUTOIMMUNITY; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; ETIOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNOLOGY;

EID: 0031240004     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4409     Document Type: Review

References (61)

1. McCartney-Francis N. L., Wahl S. M. Transforming growth factor-beta: a matter of life and death. J. Leukocyte Biol. 55:1994;401-409.
2. Roberts A. B., Sporn M. B. The transforming growth factors-β Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors. 1990;Springer Verlag, Berlin. p. 419-472.
3. Roberts A. B., Sporn M. B. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 8:1993;1-9.
4. Munger J. S., Harpel J. G., Gleizes P. E., Mazzieri R., Nunes I., Rifkin D. B. Latent transforming growth factor-beta: Structural features and mechanisms of activation. Kidney Int. 51:1997;1376-1382.
5. Barcellos-Hoff M. H. Latency and activation in the control of TGF-β J. Mammary Gland Biol. Neoplasia. 1:1997;351-361.
6. Nunes I., Gleizes P. E., Metz C. N., Rifkin D. B. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J. Cell Biol. 136:1997;1151-1163.
7. LaMarre J., Hayes M. A., Wollenberg G. K., Hussaini I., Hall S. W., Gonias S. L. An alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in mice. J. Clin. Invest. 87:1991;39-44.
8. Barcellos-Hoff M. H., Dix T. A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol. Endocrinol. 10:1996;1077-1083.
9. Schultz-Cherry S., Ribeiro S., Gentry L., Murphy-Ullrich J. E. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J. Biol. Chem. 269:1994;26775-26782.
10. Lowrance J. H., O'Sullivan F. X., Caver T. E., Waegell W., Gresham H. D. Spontaneous elaboration of transforming growth factor-beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J. Exp. Med. 180:1994;1693-1703.
11. Stach R. M., Rowley D. A. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor-beta and suppresses cytolytic T cell responses to unrelated alloantigens. J. Exp. Med. 178:1993;841-852.
12. Rowley D. A., Becken E. T., Stach R. M. Autoantibodies produced spontaneously by young 1pr mice carry transforming growth factor-beta and suppress cytotoxic T lymphocyte responses. J. Exp. Med. 181:1995;1875-1880.
13. Caver T. E., O'Sullivan F. X., Gold L. I., Gresham H. D. Intracellular demonstration of active TGF-beta1 in B cells and plasma cells of autoimmune mice. IgG-bound TGF-beta1 suppresses neutrophil function and host defense against Staphylococcus aureus infection. J. Clin. Invest. 98:1996;2496-2506.
14. Kim D. H., Kim S.-J. Transforming growth factor-β receptors: Role in physiology and disease. J. Biomed. Sci. 3:1996;143-158.
15. Attisano L., Wrana J. L. Signal transduction by members of the transforming growth factor-beta superfamily. Cytokine Growth Factor Rev. 7:1996;327-339.
16. Lagna G., Hata A., Hemmati-Brivanlou A., Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature. 383:1996;832-836.
17. Chen X., Rubock M. J., Whitman M. A transcriptional partner for MAD proteins in TGF-beta signalling. Nature. 383:1996;691-696.
18. Ruscetti F., Varesio L., Ochoa A., Ortaldo J. Pleiotropic effects of transforming growth factor-beta on cells of the immune system. Ann. NY Acad. Sci. 685:1993;488-500.
19. +. J. Immunol. 157:1996;1499-1507.
20. Riedl E., Strobl H., Majdic O., Knapp W. TGF-beta 1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J. Immunol. 158:1997;1591-1597.
21. Borkowski T. A., Letterio J. J., Farr A. G., Udey M. C. A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: The skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 184:1996;2417-2422.
22. Shull M. M., Ormsby I., Kier A. B., Pawlowski S., Diebold R. J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 359:1992;693-699.
23. Kulkarni A. B., Huh C. G., Becker D., Geiser A., Lyght M., Flanders K. C., Roberts A. B., Sporn M. B., Ward J. M., Karlsson S. Transforming growth factor-beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA. 90:1993;770-774.
24. Borkowski T. A., Letterio J. J., Mackall C. L., Saitoh A., Wang X.-J., Roop D. R., Gress R. E., Udey M. C. A role for TGF-β1 in Langerhans cell biology: Further characterization of the epidermal Langerhans cell defect in TGF-β1 null mice. J. Clin. Invest. 1997.
25. Takahama Y., Letterio J. J., Suzuki H., Farr A. G., Singer A. Early progression of thymocytes along the CD4/CD8 developmental pathway is regulated by a subset of thymic epithelial cells expressing transforming growth factor-beta. J. Exp. Med. 179:1994;1495-1506.
26. Plum J., De Smedt M., Leclercq G., Vandekerckhove B. Influence of TGF-beta on murine thymocyte development in fetal thymus organ culture. J. Immunol. 154:1995;5789-5798.
27. Mossalayi M. D., Mentz F., Ouaaz F., Dalloul A. H., Blanc C., Debre P., Ruscetti F. W. Early human thymocyte proliferation is regulated by an externally controlled autocrine transforming growth factor-beta 1 mechanism. Blood. 85:1995;3594-3601.
28. Kulkarni A. B., Ward J. M., Geiser A. G., Letterio J. J. TGF-β1 Knockout mice: Immune dysregulation and pathology. Abraham N. G., Shadduck R. K., Levine A. S., Takaku F. Molecular Biology of Hematopoiesis. 1994;749-757 Intercept Ltd. Andover.
29. Nakabayashi T., Letterio J. J., Kong N., Ogawa N., Dang H., Talal N. Upregulation of cytokine mRNA, adhesion molecule proteins and MHC class II proteins in salivary glands of TGF-β1 knockout mice: MHC class II is a factor in the pathogenesis of TGF-β1 knockout mice. J. Immunol. 158:1997;5527-5535.
30. Dang H., Geiser A. G., Letterio J. J., Nakabayashi T., Kong L., Fernandes G., Talal N. SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J. Immunol. 155:1995;3205-3212.
31. Wahl S. M. Transforming growth factor beta: The good, the bad, and the ugly. J. Exp. Med. 180:1994;1587-1590.
32. Border W. A., Noble N. A. Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331:1994;1286-1292.
33. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 334:1988;260-262.
34. Ming M., Ewen M. E., Pereira M. E. Trypanosome invasion of mammalian cells requires activation of the TGF-beta signaling pathway. Cell. 82:1995;287-296.
35. Barral-Netto M., Barral A., Brownell C. E., Skeiky Y. A., Ellingsworth L. R., Twardzik D. R., Reed S. G. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science. 257:1992;545-548.
36. Kopp J. B., Factor V. M., Mozes M., Nagy P., Sanderson N., Bottinger E. P., Klotman P. E., Thorgeirsson S. S. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab. Invest. 74:1996;991-1003.
37. Racke M. K., Dhib-Jalbut S., Cannella B., Albert P. S., Raine C. S., McFarlin D. E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol. 146:1991;3012-3017.
38. Racke M. K., Cannella B., Albert P., Sporn M., Raine C. S., McFarlin D. E. Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int. Immunol. 4:1992;615-620.
39. Racke M. K., Sriram S., Carlino J., Cannella B., Raine C. S., McFarlin D. E. Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 2. J. Neuroimmunol. 46:1993;175-183.
40. Santos L. M., al-Sabbagh A., Londono A., Weiner H. L. Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice. Cell Immunol. 157:1994;439-447.
41. Miller A., Lider O., Roberts A. B., Sporn M. B., Weiner H. L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor-beta after antigen-specific triggering. Proc. Natl. Acad. Sci. USA. 89:1992;421-425.
42. Chen Y., Kuchroo V. K., Inobe J., Hafler D. A., Weiner H. L. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science. 265:1994;1237-1240.
43. ++. J. Immunol. 155:1995;910-916.
44. Strober W., Kelsall B., Fuss I., Marth T., Ludviksson B., Ehrhardt R., Neurath M. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol. Today. 18:1997;61-64.
45. Marth T., Strober W., Kelsall B. L. High dose oral tolerance in ovalbumin TCR-transgenic mice: Systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. J. Immunol. 157:1996;2348-2357.
46. Wakefield L. M., Sporn M. B. Suppression of carcinogenesis: A role for TGF-beta and related molecules in prevention of cancer. Immunol. Ser. 51:1990;217-243.
47. Markowitz S. D., Roberts A. B. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 7:1996;93-102.
48. Hahn S. A., Schutte M., Shamsul Hoque A. T. M., Moskaluk C. A., da Costa L. T., Rozenblum E., Weinstein C. L., Fischer A., Yeo C. J., Hruban R. H., Kern S. E. DPC4, Science. 271:1996;350-353.
49. Eppert K., Scherer S. W., Ozcelik H., Pirone R., Hoodless P., Kim H., Tsui L. C., Bapat B., Gallinger S., Andrulis I. L., Thomsen G. H., Wrana J. L., Attisano L. MADR2 maps to 18q21 and encodes a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 86:1996;543-552.
50. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R. S., Zborowska E., Kinzler K. W., Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
51. Knaus P. I., Lindemann D., DeCoteau J. F., Perlman R., Yankelev H., Hille M., Kadin M. E., Lodish H. F. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol. Cell Biol. 16:1996;3480-3489.
52. Kadin M. E., Cavaille-Coll M. W., Gertz R., Massague J., Cheifetz S., George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc. Natl. Acad. Sci. USA. 91:1994;6002-6006.
53. Böttinger E. P., Jakubczak J. L., Roberts I. S. D., Mumy M., Hemmati P., Bagnall K., Merlino G., Wakefield L. M. Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J. 16:1997.
54. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X. F., Shimizu J., Fujiwara H., Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 146:1991;1077-1082.
55. Torre-Amione G., Beauchamp R. D., Koeppen H., Park B. H., Schreiber H., Moses H. L., Rowley D. A. A highly immunogenic tumor transfected with a murine transforming growth factor type-beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA. 87:1990;1486-1490.
56. Weiskirch L. M., Bar-Dagan Y., Mokyr M. B. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol. Immunother. 38:1994;215-224.
57. Fakhrai H., Dorigo O., Shawler D. L., Lin H., Mercola D., Black K. L., Royston I., Sobol R. E. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. USA. 93:1996;2909-2914.
58. Wojtowicz-Praga S., Verma U. M., Wakefield L., Esteban J. M., Hartmann D., Mazumder A. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J. Immunother. Emphasis Tumor Immunol. 19:1996;169-175.
59. Arteaga C. L., Hurd S. D., Winnier A. R., Johnson M. D., Fendly B. M., Forbes J. T. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 92:1993;2569-2576.
60. Hoefer M., Anderer F. A. Anti-(transforming growth factor-beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol. Immunother. 41:1995;302-308.
61. Qin L., Ding Y., Bromberg J. S. Gene transfer of transforming growth factor-beta 1 prolongs murine cardiac allograft survival by inhibiting cell-mediated immunity. Hum. Gene Ther. 7:1996;1981-1988.